Guillaume Pfefer, CEO of Sail Biomedicines and CEO-Partner at Ä¢¹½ÊÓƵAPP, explains how the company’s platform is unlocking fully programmable medicines and shares more on two recently announced partnered programs targeting malaria and cystic fibrosis. More from Flagship @ JPM2024 here.
Related Companies
- Sail Biomedicines Founded: 2017 / 2023